Efficacy Evaluation and Influencing Factors of Argon Laser Peripheral Iridoplasty in Acute Angle Closure Glaucoma

NCT04912310 | Unknown

• 1 other identifier: 2020-480
• Study Type: interventional
• Target: 65
• Locations: 1 country
• Sites: 1

Brief Summary

To investigate the changes of angle structure and intraocular pressure after argon laser peripheral iridoplasty in patients with acute angle closure glaucoma patients whose intraocular pressure could not be controlled by drug therapy during the major attack period.

Conditions

Acute Angle-Closure Glaucoma

Keywords

Acute angle-closure glaucoma; Argon laser peripheral iridoplasty

Outcome Measures

Primary Outcomes (1)

• Intraocular pressure

  Intraocular pressure

  6 weeks

Study Arms (1)

Acute angle closure glaucoma

EXPERIMENTAL

Argon laser peripheral iridoplasty

Device: Argon laser peripheral iridoplasty

Interventions

Argon laser peripheral iridoplasty DEVICE

Argon laser peripheral iridoplasty was performed in patients with severe acute angle closure glaucoma whose intraocular pressure could not be controlled by medication

Acute angle closure glaucoma

Eligibility Criteria

• Age: 40 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• One eye had an acute attack, which could not be relieved by medication, and the intraocular pressure was more than 21mmhg;
• The patients were 40 to 80 years old, regardless of gender;
• Patients are able and willing to comply with the research guidance and may complete all visits required by the research;
• Informed consent has been signed.

You may not qualify if:

• History of ocular trauma;
• Any previous intraocular surgery;
• Secondary glaucoma was diagnosed, including uveitis, neovascular glaucoma, glaucoma with elevated superior scleral venous pressure, lens dissolution glaucoma, glaucoma caused by lens dislocation, lens cortical glaucoma, pigmented glaucoma, etc;
• The patient's history indicated that he had severe dysfunction of heart, lung, liver and kidney;
• Women in pregnancy, lactation or planned pregnancy;
• The researchers believe that the patient's condition may put the patient at a significant risk, may confuse the results of the study, or may significantly interfere with the patient's participation in the study.

Sponsors & Collaborators

• Second Affiliated Hospital, School of Medicine, Zhejiang University: lead

Study Sites (1)

Eye center, 2nd Affiliated Hospital, School of Medicine, Zhejiang University,

Hangzhou, Zhejiang, China

RECRUITING

Study Officials

• kaijun wang, MD

  2nd Affiliated Hospital, School of Medicine, Zhejiang University, China

  STUDY DIRECTOR

Central Study Contacts

kaijun wang, MD

CONTACT

+86 0571 87783759; wkj992@126.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 31, 2021
• First Posted: June 3, 2021
• Study Start: July 13, 2020
• Primary Completion: July 1, 2021
• Study Completion: July 1, 2021
• Last Updated: June 3, 2021

Record last verified: 2020-07

Locations

CN (1)